Pfizer (PFE) has been in talks with the Trump administration to receive a priority voucher under a new FDA pilot program that would cut the review of one its drugs to one to two months from the standard 10 to 12 months.
CEO Albert Bourla told Bloomberg that the administration has spoken with the administration about the vouchers, but declined to say which drugs are under consideration for getting one.
Several large pharmas have already been awarded vouchers, including Eli Lilly (LLY), Novo Nordisk (NVO), and Sanofi (SNY).
Pfizer was one of the first drug companies to ink a deal with the Trump administration to offer discounts on some of its drugs as part of the president’s “most favored nation” program.
